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 Abstract 
Objectives:   The aim of this study was to determine the influence of non-ionisable excipients 
hydroxypropyl-E-cyclodextrin (HPECD) and poloxamers 407 and 188 on the supersaturation and 
precipitation kinetics of ibuprofen, gliclazide, propranolol and atenolol induced through solution pH 
shifts using the CheqSol method.    
Methods:   The GUXJ¶Vkinetic and intrinsic aqueous solubility was measured in the presence of 
increasing excipient concentrations using the CheqSol solubility method.   Experimental data for 
example rate of change of pH with time was also examined to determine excipient induced 
parachute effects and influence on precipitation rates.    
Key Findings:   The measured kinetic and intrinsic solubilities provide a determination of the 
influence of each excipient on supersaturation index and the area under the CheqSol curve can 
measure the parachute capability of excipients.   The excipients influence on precipitation kinetics 
can be measured with novel parameters for example the precipitation pH or percentage ionized 
drug at the precipitation point which provide further information on the excipient induced changes 
in precipitation performance.    
Conclusion:   This method can therefore be employed to measure the influence of non-ionisable 
excipients on the kinetic solubility behavior of supersaturated solutions of ionisable drugs and to 
provide data, which discriminates between excipient systems during precipitation.    
 
 Introduction 
Solubility 
$ GUXJ¶V DTXHRXV VROXELOLW\ is a key parameter controlling its pharmaceutical development [38], 
formulation [32] and biopharmaceutical properties [28].   For oral administration the effect of 
solubility on bioavailability has been encapsulated in the biopharmaceutics classification system [1] 
where it is recognized that drugs with a low solubility with respect to dose will potentially have a 
limited bioavailability [18].   For parenteral therapy, the issue of precipitation after injection of a 
poorly soluble drug [47] inducing phlebitis [23] is a recognized problem.   The current trend is 
towards the generation of molecules with increasing lipophilicity and consequently decreasing 
aqueous solubility [17], which necessitates enhanced solubility formulations for parenteral [39] and 
oral [32] administration using a variety of techniques [43].   The experimental measurement of drug 
solubility and solution physical stability is therefore an important activity during development and 
three key solubility measures are recognized; the intrinsic, equilibrium and kinetic solubilities.    
 
Measures of Solubility 
Intrinsic solubility is a measure of the neutral (non-ionised) PROHFXOH¶Vmaximum solubility [46] in 
solution, which for ionizable molecules requires suppression of ionization by the use of an 
appropriate pH.   Equilibrium or thermodynamic solubility includes solubility of both un-ionised and 
ionised species using a defined aqueous system (pH and presence of other salts) and employing 
the most stable solid form in the solution.   Either value can be measured using classical shake-
flask methods [13] where an excess of solid drug is mixed with a buffered solution phase until 
equilibrium between the solid and solubilized drug is achieved.   Kinetic (or apparent) solubility is a 
measure of the maximum solubility achieved by creating supersaturated aqueous solutions with 
concentrations greater than the equilibrium solubility (see [7] for definition of supersaturation) 
either by dissolution of a high energy solid form [16], dilution of high concentration water miscible 
solvent solutions [44] or via aqueous solution pH shifts [5] (see Figure 1a), which alter the 
ionization ratio and therefore equilibrium solubility.   Since these supersaturated systems exceed 
the equilibrium solubility they are thermodynamically unstable, have to be created dynamically and 
have a tendency to precipitate to the equilibrium solubility value with time [16].    
 
Investigation of Supersaturation 
Assisted solubility formulations therefore present drug, irrespective of route of administration, in a 
supersaturated state [47; 21; 7] with respect to the biopharmaceutical environment in an attempt to 
increase delivery and or absorption.   However, this can result in precipitation upon administration 
and the bioavailability or toxicity problems detailed above.   Multiple experimental methods have 
been introduced to evaluate the precipitation performance of supersaturated systems [10] for 
intravenous therapy [27] or solid oral dosage forms [41].   For the oral route, drug is administered 
generally as a solid form, which requires dissolution prior to absorption and therefore the initial 
creation of the supersaturated solution occurs during the dissolution process.   This has led to the 
SURSRVDORIWKH³VSULQJ´DQG³SDUDFKXWH´K\SRWKHVLVZKHUHWKHGUXJ¶VSK\VLFDOIRUPRUpresence of 
formulation excipients springs the drug into supersaturated solution with subsequent precipitation 
inhibited (parachute) by the formulation excipients [16].   The spring effect or supersaturation can 
be quantified by determining the maximum supersaturation index achieved [7], which measures 
the apparent solubility increase over equilibrium solubility.   The parachute effect can be 
determined using the recently proposed excipient gain factor [3], which measures the increased 
area under the solubility time curve due to the excipients inhibiting precipitation to the equilibrium 
solubility value.   Several studies have applied this model to screen excipients for solubility 
improvements, using solvent induced [41], solvent evaporation [11] or solid form [16] techniques to 
create the initial supersaturated solution.    
 
One alternative method of inducing supersaturation is to shift the pH of an already saturated 
solution of an ionisable drug to increase the percentage of non-ionised species present, which 
reduces the V\VWHP¶V equilibrium solubility and creates supersaturation [46].   This property is 
utilized in the chasing equilibrium solubility or CheqSol approach [40] which relies on pH changes 
produced by the addition of acid or base, to change the ratio of non-ionised to ionised drug present 
and to alternate between supersaturated and subsaturated conditions permitting the determination 
of both the kinetic and intrinsic solubility (see Figure 1a).   This technique, which was initially aimed 
at early drug development and candidate screening studies [5], should however be applicable to 
situations where determination of solubility is required such as parenteral formulation development 
[35] or crystallization [22].   Recently we have employed this technique to determine solubility 
increases associated with the solubility enhancing excipients hydroxypropyl-E-cyclodextrin 
(HPECD) and the poloxamers 407 and 188 [14].   Since these excipients are non-ionisable the 
CheqSol method was able to measure their influence on the solubility of test ionisable drugs, 
determining excipient concentration dependent increases in both intrinsic and kinetic solubility 
values.   For the intrinsic solubility these measurements were comparable to previously published 
traditional shake flask methods [15].   However during the conduct of this study it was noted other 
experimental parameters were changing [14] and indicated that since the CheqSol method was 
dynamic [5], it may also be determining spring and parachute type behavior and the precipitation 
kinetics.   In this paper we have employed the CheqSol method to examine the influence of the 
non-ionising excipients hydroxypropyl-E-cyclodextrin and the poloxamers 407 and 188 on the 
precipitation behavior of four test drugs; the acids ibuprofen and gliclazide and the bases atenolol 
and propranolol.   Results indicate that the method can measure parachute behavior and provide 
novel insight into an excipients ability to maintain supersaturation and influence precipitation 
behaviour.    
 
Materials and Methods 
Materials 
Propranolol HCl (base pKa 9.54), atenolol (base pKa 9.48), ibuprofen (acid pKa 4.35), gliclazide 
(acid pKa 5.54) and poloxamers 407 and 188 were obtained from Sigma-Aldrich Company Ltd 
(Dorset, UK).  HP-ȕ-CD (Cavitron 82004) was obtained from Cargill (Cedar Rapids, Iowa, USA).  
0.5M Potassium hydroxide (KOH) (Fisher Scientific, Loughborough, Leicestershire, UK) was 
prepared from 1 mole vial of KOH diluted to 2 L with HPLC grade water.  0.5M Hydrochloric acid 
(HCl) (Fisher Scientific, Loughborough, Leicestershire, UK) was used as purchased.  HPLC grade 
water was obtained using an Elga UHQ2 system (Marlow, Buckinghamshire, UK).    
 
Methods 
Experiments were carried out using the Sirius T3 titrator (Sirius Analytical Instruments Ltd, East 
Sussex, UK), in ionic strength adjusted (ISA) water containing 0.15M potassium chloride, obtained 
from VWR (Leuven, Belgium), in HPLC grade water.  Experiments were conducted at a 
temperature of 25oC ± 0.5oC under an argon atmosphere.  The apparatus was connected to and 
run from Sirius software on a Dell desktop.  The T3 set up includes a Ag/AgCl double junction 
reference pH electrode, a Peltier temperature control device, with thermocouple temperature probe, 
an overhead stirrer (variable speed, computer controlled).  The spectrophotometer was a MMS 
UV±VIS Carl Zeiss Microimaging spectrophotometer with an ultra-mini immersion probe attached 
(Welwyn Garden City, Hertfordshire, UK.). 
 
Potentiometric determination of solubility 
Solubility determination was carried out using the CheqSol assay [40].   The drug was weighed into 
a vial and +3ȕ&'RUSROR[DPHUZDVDGGHGLIUHTXLUHG.   The mass of drug used varied depending 
on the expected solubility.  ISA water volumes of 1.5 mL (propranolol HCl, gliclazide and 
ibuprofen) or 1 mL (atenolol) were added before the pH was adjusted to solubilise the drug at a pH 
where ionisation was expected.   After dissolution of the sample was complete detected by pH 
changes, the sample was titrated from ionisation to non-ionisation through addition of acid or base 
until precipitation of the non-ionised form was detected.   The concentration at precipitation, 
determined using the principles of mass and charge balance, is equivalent to the kinetic solubility.  
After this point more titrant was added to increase precipitation.   Thereafter, as the solubility re-
adjusts towards the equilibrium solubility, alternating aliquots of acid and base were added to 
induce subsaturation and supersaturation.   This would be continued until twenty crossing had 
been titrated.   A crossing point is where the pH change versus time ǻS+ǻW LV ]HUR and the 
system would be at equilibrium [4].   The concentration at each crossing point is calculated using a 
series of mass and charge balance equations, [40], intrinsic solubility is the mean of the crossing 
point concentrations.   Crossover plots display the concentration of unionised drug during 
subsaturation and supersaturation and each crossing point shows the intrinsic solubility.   The 
solubility was determined for the drugs on their own DQGLQWKHSUHVHQFHRI+3ȕCD at molar ratios 
of 1:0.1, 1:0.5, 1:1, 1:1.5 and 1:2 (for exact detail see results) and poloxamer surfactants 407 and 
188 at concentrations of 0.5, 1.0, 2.0. 5.0 and for poloxamer 188 additionally at 10 % w/v.   The 
kinetic information associated with each determination, equilibrium chasing cross over plot, 
precipitation rate graph and neutral species concentration profile were extracted.    
 
Determination of the intrinsic and kinetic solubilities of a drug solubiliser system permits calculation 
of the supersaturation index (Equation 1) [34], which maybe calculated using the intrinsic solubility 
in the absence or presence of the excipient.   Note that due to the dynamic nature of the CheqSol 
measurement technique the determination is not thermodynamically competent since the kinetic 
and intrinsic solubilities are not measured under identical conditions [40].   Nevertheless, useful 
trends in supersaturation behaviour can be observed.   
 
Equation 1.   
 
The area under the solubility time curve of the CheqSol measurement was calculated using a 
trapezoidal rule on the determined neutral species concentration with time (s) (see Figure 1a).   
CheqSol experiments have durations of around 5,000 s with the majority of time related to the 
determination of equilibrium solubility.  To standardise results and provide a balance of 
supersaturation and equilibrium contributions areas under the curve out to 2,500 s were calculated.  
Excipient gain factors were determined (Equation 2). 
 
Equation 2.   
 
Statistical Analysis of Results 
Values were compared using a one-way non-parametric Kruskal-:DOOLVWHVWIROORZHGE\D'XQQ¶V
multiple comparison test against the value for the drug alone using Prism 6 for Mac OSX.  
 
 
Results 
Supersaturation Index 
The calculated supersaturation index values based on the measured kinetic and intrinsic solubility 
for all drug excipient combinations tested are presented in Table 1.   For HPECD the 
supersaturation index based on aqueous intrinsic solubility (see Table legend) increases for 
ibuprofen, gliclazide and propranolol as the HPECD molar ratio or concentration increases, and is 
statistically significant at the higher excipient concentrations/ratios tested.   For atenolol there is no 
significant change with HPECD concentration increases.   A similar pattern is observed for both 
poloxamers.   ,I WKH VXSHUVDWXUDWLRQ LQGH[ LV FDOFXODWHGXVLQJHDFKVROXWLRQ¶VPHDVXUHG LQWULQVLF
solubility value (instead of intrinsic solubility in the absence of excipient), a different pattern 
emerges.   In most cases the supersaturation index value remains constant but in some cases the 
value is significantly lower than the value for drug alone, for example gliclazide with poloxamer 188, 
and HPECD with ibuprofen and propranolol.   
 
Excipient Gain 
The CheqSol method relies on measuring solution pH changes induced by the addition of acid or 
base to determine solubility [40] starting with drug in solution and then shifting pH to create a 
supersaturation which precipitates and is then followed by a chasing phase measuring rates of 
change of pH with time (dpH/dt).   Typical results for propranolol are presented in Figure 1, with full 
experimental traces in the inset graph and the main graph expanded to cover the initial 
supersaturation and equilibrium phases.   Calculated area under the curve (AUC) and excipient 
gain factors are presented in Figures 2a and b and whilst not identical to the solubility based 
supersaturation index results presented in Table 1 the values follow the same trends.   Ibuprofen 
(Figure 2a) exhibits the greatest area increases and therefore excipient gains followed by 
propranolol and gliclazide, atenolol does not register an excipient gain greater than 2 with any of 
the excipients.    
 
Precipitation Parameters 
During the chasing portion of the CheqSol analysis acid and base additions are cycled to force the 
system to dissolve or precipitate allowing determination of the intrinsic solubility.   During this 
phase the rate of change of pH with respect to time (dpH/dt) is measured and sample results for 
propranolol are presented in Figure 3 for the drug on its own and in the presence of selected 
concentrations of each of the three excipients employed.   It is obvious that the presence of the 
excipients increases the measured solubility by shifting the equilibrium chasing point to higher 
concentrations [14].   Based on the dpH/dt data the CheqSol method determines precipitation 
parameters (precipitation concentration i.e., x-axis crossing point (µM), precipitation rate (µM/min) 
and precipitation pH) for each experiment and this data is collectively presented in Figure 4a and b.   
HPECD significantly increases the precipitation concentration of ibuprofen, gliclazide and 
propranolol (Figure 4a, first panel, middle graph) in a concentration dependent manner, whilst the 
results for atenolol are highly variable (Figure 4b) with a trend of increasing precipitation 
concentration as HPECD concentration increases.   For all drugs and both poloxamers a 
statistically significant increase in precipitation concentration is evident as excipient concentration 
increases (Figures 4a and b, second and third panels, middle graphs), which is comparable to the 
effects of HPECD.   This change is associated with a significant decrease in the HPECD 
precipitation pH (Figure 4a first panel, lower graph) for the acidic drugs (ibuprofen and gliclazide) 
or increase for the basic drug (propranolol).   The effect of poloxamers on precipitation pH is 
complex with a significant reduction in pH for atenolol and some propranolol ratios whilst for 
ibuprofen and gliclazide there is an increase at low poloxamer concentrations followed by a 
general increase in precipitation pH.    
 
HPECD significantly reduces the precipitation rate of ibuprofen, gliclazide and propranolol in a 
concentration dependent manner (Figure 4a first panel, top graph) whilst the effect of poloxamers 
is complex with atenolol exhibiting no change and for ibuprofen and propranolol (Figure 4a second 
and third panels, top graph) an increase at low excipient concentrations followed by a minimum 
then further increases to values significantly greater than those of the drug alone.   For gliclazide 
the precipitation rate increases at low poloxamer concentrations and then reduces as the excipient 
concentration is increased.    
 
Excipient Characteristics 
Further data comparisons are possible, since the CheqSol mass balance calculation also provides 
the percentage of drug ionization at the cross over point and Figure 5 presents the percentage 
ionization plotted against the precipitation rate for each drug.   This reinforces the differences 
between the excipients presented above with HPECD decreasing the precipitation rate and 
percentage ionization required for precipitation for propranolol, gliclazide, and ibuprofen, whilst the 
poloxamers exhibit a different profile for each drug.   The latter result indicates differential 
interactions between the drugs and poloxamers that would not be detected using the excipient gain 
analysis.    
 
Discussion 
The majority of published studies on HPECD [29; 15] or poloxamer solubilisation [25] involve 
equilibrium methods, which determine intrinsic/equilibrium solubility not supersaturation and 
indicate that HPECD and poloxamer excipients have the ability to enhance the intrinsic solubility of 
the drugs tested.   This study indicates that the excipients can also provide supersaturated 
solutions of ibuprofen, gliclazide and propranolol during pH induced intrinsic solubility changes with 
the measured supersaturation index excipient concentration dependent.   Atenolol is the exception 
with no appreciable change, possibly because this drug has the highest aqueous solubility [14] of 
all the drugs tested which provided a practical experimental limit based around drug solubility, 
excipient concentration, reaction volume and acid/base strengths.   Recent studies involving 
HPECD and non-ionic surfactants [41; 6; 7] also illustrate the ability of these excipients to maintain 
supersaturated systems created using solvent based methods.   The supersaturation values 
reported in this study are similar, however the extent of supersaturation reported in the cited 
studies is large and ranges from zero to greater than one thousand, and only a single excipient 
concentration is tested limiting the applicability of the comparison.   Supersaturation values 
UHSRUWHG IRUDG\SULGDPROH&DYDVROFRPELQDWLRQXVLQJ WKH&KHT6RO WHFKQLTXH [4] ranged from 
twenty to nine again indicating comparability with this study.   It has been reported for a topical 
formulation system consisting of ibuprofen and propylene glycol [21] that increasing the excipient 
concentration increases the intrinsic solubility and degree of supersaturation with comparable 
supersaturation values to those reported in this study.   Finally the supersaturation value measured 
within a solution using the VROXWLRQ¶VLQWULQVLFVROXELOLW\VLJQLILFDQWO\GHFUHDVHVLQVRPHV\VWHPVDV
the excipient concentration increases.   This decrease is also present for the ibuprofen/propylene 
glycol and dypridamole/Cavasol systems as the excipient concentration increases and indicates an 
interesting limitation with respect to drug, excipient ratio and potential supersaturation achievable 
as intrinsic solubility increases.    
 
It is obvious that the excipients increase the pH induced supersaturation (higher peak neutral 
species concentration) and equilibrium solubility but changes to the experimental FXUYH¶V VKDSH
are also evident.   These changes DUHVLPLODUWRWKRVHSUHVHQWHGIRU³VSULQJDQGSDUDFKXWH´W\SH
systems [16] and therefore amenable to a comparative area under the curve (AUC) analysis to 
determine excipient gain factors.   Due to the nature of the CheqSol method AUC results 
incorporate supersaturation and equilibrium solubility with excipient free experiments providing the 
GUXJ¶V VXSHUVDWXUDWLRQ IDFWRU [3]   ,Q DGGLWLRQ WKH LQLWLDO S+ VKLIW LV HPSOR\HG DV WKH ³VSULQJ´ WR
create supersaturation not addition of a water miscible solvent solution or high solubility 
amorphous form.   All three excipients are known to assist supersaturation and Guzman et.al., [16] 
reports that poloxamers can inhibit precipitation of celecoxib for over 60 minutes.   Hsieh et.al., [20] 
have reported on the precipitation behaviour of weak bases and reported similar curves to this 
study but did not examine the influence of excipients.   The results indicate that for ibuprofen, 
gliclazide and propranolol, HPECD and poloxamer 407 and 188 can act as parachutes increasing 
the measured AUC in a concentration and drug excipient combination dependent manner.   For 
atenolol there is very little relative change in area indicating that none of the excipients are 
influencing behaviour in this system.    
 
The shift of pH in the presence of excipients has been previously employed in potentiometric 
studies of cyclodextrin inclusion complexes [9] to determine binding constants and to study the 
interaction of drugs with surfactants [33; 12] and lipid phases [8] to determine partition coefficients.   
Changes in the measured slope of the dpH/dt line indicate DQ H[FLSLHQW HIIHFW RQ WKH DVVD\¶V
kinetic behaviour, which is to be expected since both excipient types are known to influence the 
solution behaviour and solubility of small molecules [24; 30; 14].   Although precipitation and 
determination of precipitation rate is an integral feature of the dynamic nature of CheqSol [40], 
which has been employed to determine the solubility of multiple drugs [36] and the influence of 
polymers on precipitation [4; 20; 14; 19], no data on the measured precipitation rates have been 
presented.   The previously mentioned potentiometric studies [33; 9; 8; 12] utilized systems at 
equilibrium and precipitation rates were not determined.   This study therefore is the first 
examination of the influence of excipients on precipitation rate and the results indicate interesting 
differences in behaviour between HPE&'DQG WKHSROR[DPHUVZLWK WKH IRUPHU¶VHIIHFW GXHPRVW
likely to its formation of an inclusion complex whilst for the latter micellar solubilisation provides a 
reservoir that can easily precipitate once solution conditions allow.    
 
The precipitation from supersaturated pharmaceutical system has been extensively investigated 
[10; 45] however, literature comparisons with this study are limited for a range of reasons.   The 
PDMRULW\ RI PHWKRGV FUHDWH D ³VWDQGDUG´ PHWD-stable supersaturated system, then examine the 
influence of excipients on time taken for a precipitate to IRUP ³QDWXUDOO\´ [3] and report results 
based on an excipient induced precipitation time delay when compared to a free drug system (for 
example [16]).   CheqSol continuously changes pH in the required direction until precipitation is 
induced [40] to determine kinetic solubility and then cycles pH to determine intrinsic solubility.   In 
addition most studies report the influence of a single excipient concentration [16; 6] and not the 
influence of a concentration range.   However, despite these differences it is obvious that the 
method is capturing and providing quantitative information on the excipients influence on 
precipitation behaviour and providing data, which discriminates between HPECD and the 
poloxamers.   Both excipients for example provide an excipient gain (Figure 2), which has been 
reported in the literature but with very different effects on precipitation rates (Figure 4) and 
percentage drug ionization (Figure 5) at precipitation, which has not been previously reported.   
This data may be useful to determine DGUXJH[FLSLHQWFRPELQDWLRQ¶VDSSOLFDELOLW\ for a particular 
setting, for example the slower precipitation rate of HPECD might be better suited to conditions 
where rapid changes inducing precipitation is expected and the poloxamer to situations where a 
more stable environment can support supersaturation.   
 
The theoretical equations describing the interactions between weak acids or bases with surfactants 
or cyclodextrins ZHUHSXEOLVKHGLQWKH¶V[33; 9] and several studies have employed these to 
determine binding constants [37].   However, these have been conducted under equilibrium 
conditions usually over a range of pH values covering at least 2 pH units either side of the pKa and 
not always in the presence of solid drug.   The CheqSol experiment dynamically explores this 
system with a limited pH range (see Figure 4 lower graphs), which does not permit determination 
of the binding constants.   In addition the presence of solid drug, excipient and dynamic 
precipitation and dissolution events present a complex system.   It is known for example that 
excipients in solution can interfere with precipitation and crystal growth [42; 19] and that buffer 
physicochemistry can influence cyclodextrin complexation [31].   Analysis to provide rate constants 
from the results is therefore not sensibly feasible, however modification of the analysis to for 
example cover a wider pH range, coupled with control experiments which do not involve 
precipitation [14] could permit a full kinetic analysis.    
 
The investigation of precipitation from supersaturated systems is to determine and understand 
behaviour that can be related to biopharmaceutical performance, which for pH and parenteral 
administration is a shift to pH 7.4 [27] and for oral from stomach acid to the higher intestinal pH 
[26].   Since CheqSol utilizes pH induced supersaturation the direction of pH change is 
automatically appropriate for weak bases for intestinal transfer but not for weak acids. In the former 
case the propranolol experiments were conducted around pH 8-9 and atenolol at pH 10-11, which 
do not represent typical intestinal pH [2] values and therefore not biorelevant, an argument which 
can also be applied to the parenteral situation for both acids and bases. Nevertheless, results are 
determined for precipitation of the unionised species and total solubilities could be calculated for 
other pH values.   The atenolol results also highlighted an experimental limitation with respect to 
the balance of intrinsic drug solubility, pKa, instrument titration volume (1-5mL) and acid/base 
titration strengths.   Modification of the experimental parameters or utilization of a different 
experimental platform could alleviate some of these issues.    
 
Conclusion 
The results presented in this paper indicate that for non-ionisable excipients and ionisable drugs 
the CheqSol method can be employed to determine the influence of excipients on supersaturation 
and precipitation.   Determination of parachute and excipient gain properties are possible with 
results that are broadly comparable to related published methods but which provide a degree of 
quantitative measurement.   The measured precipitation rates provide the ability to discriminate 
between excipients, which both exhibit parachute type activity but produce this through different 
mechanisms.   Modification of the method to permit a more comprehensive kinetic analysis, 
expand drug applicability and increase biorelevance is also possible.   Overall the method 
represents a useful orthogonal approach to assessing precipitation, provides expanded excipient 
performance information and could be employed as a quantitative and qualitative excipient 
screening system.    
 Table 1 
Title: Supersaturation index calculated from solubility analysis results in the presence of non-
ionisable excipients. 
Legend: Supersaturation index calculated using Equation 1 and the measured kinetic and 
instrinsic solubility values.   Solution Intrinsic column calculated using the measured 
intrinsic solubility value for each system.   Aqueous Intrinsic column calculated using 
the measured intrinsic solubility for the aqueous system in the absence of excipients.   
Mean ± standard deviation, n as stated in Table, * Statistically significant difference P < 
0.05 compared to control result with no excipient. 
 
Figure 1. 
Title: CheqSol Solubility Determination. 
Figure 1a. 
Title: Schematic of CheqSol solubility determination. 
Legend: Figure 1a.   Progress of CheqSol solubility determination indicating measurement of 
kinetic and instrinsic solubilities and area under the curve. 
 
Figure 1b. 
Title: Propranolol CheqSol determination in the absence and presence of selected 
concentrations of non-ionisable excipients. 
Legend: Figure 1.   Propranolol: { Free drug;  Hydroxypropyl-ȕ-cyclodextrin 1:1 
drug:cyclodextrin molar ratio; U poloxamer 407 2% w/v;  poloxamer 188 2% w/v.   
Inset graph, identical symbols, complete experimental data presented. 
 
Figure 2a and b 
Title: Effect of non-ionisable excipient concentrations on CheqSol curve areas and 
calculated excipient gain factors of Propranolol, Ibuprofen, Gliclazide and Atenolol.    
Legend: )LJXUH D¨ 3URSUDQRORO R ,EXSURIHQ Gliclazide, mean ± standard deviation (n = 
see Table 1), * statistically significant difference from drug alone P < 0.05.    
 Figure 2b: o Atenolol, mean ± standard deviation (n = see Table 1), * statistically 
significant difference from drug alone P < 0.05.    
 
 
Figure 3 
Title: Measured dpH/dt values for propranolol during CheqSol determination in the absence 
and presence of selected concentrations of non-ionisable excipients. 
Legend: Figure 3.   Propranolol: Ŷ )UHH GUXJ ź +\GUR[\SURS\O-ȕ-cyclodextrin 1:0.2 
GUXJF\FORGH[WULQ PRODU UDWLR Ɣ SROR[DPHU   ZYی poloxamer 188 10% w/v.   
Closed symbols measured dpH/dt values, open symbols determined crossing points. 
 
Figure 4a and b 
Title: Effect of non-ionisable excipient concentrations on CheqSol precipitation parameters of 
propranolol, ibuprofen, gliclazide and atenolol.    
Legend: Figure 4a: ¨ Propranolol; o Ibuprofen;  Gliclazide, mean ± standard deviation (n = 
see Table 1), * significantly different from drug alone P < 0.05.   Figure 4b: Atenolol, 
mean ± standard deviation (n = see Table 1), * significantly different from drug alone P 
< 0.05.    
 
Figure 5. 
Title: Effect of Excipient Concentration on Precipitation Rate and Percentage Ionisation.   
Legend: Figure 5: ƔExcipient Free Drug; o Hydroxypropyl-ȕ-F\FORGH[WULQ¨3ROR[DPHU 
Poloxamer 188. Plot symbol size represents excipient concentration, values indicate 
concentration in mM.     
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Figure 3.   Measured dpH/dt values for propranolol during CheqSol determination in the absence and presence of selected concentrations of non-
ionisable excipients.
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Table&1.&&Supersaturation&index&calculated&from&CheqSol&solubility&analysis&results&in&the&presence&of&non;ionisable&excipients.&
Hydroxypropyl;b;cyclodextrin&
Ibuprofen& & Gliclazide& & Atenolol& & Propranolol&
Molar&
ratio&
Solution&
intrinsic&
Aqueous&
intrinsic&
& Molar&
ratio&
Solution&
intrinsic&
Aqueous&
intrinsic&
& Molar&
ratio&
Solution&
intrinsic&
Aqueous&
intrinsic&
& Molar&
ratio&
Solution&
intrinsic&
Aqueous&
intrinsic&
0.00(n=4)& 3.980.50& 3.980.50& & 0.00(n=3)& 27.505.78& 27.505.78& & 0.00(n=5)& 2.632.19& 2.632.19& & 0.00(n=3)& 4.470.05& 4.470.05&
0.10(n=5)& 3.840.69*& 6.021.08& & 0.11(n=3)& 6.730.78& 16.221.88& & 0.05(n=3)& 1.360.11& 1.690.14& & 0.10(n=3)& 1.160.08& 5.780.37&
0.50(n=5)& 2.700.20& 18.071.33&& 0.50(n=3)& 32.701.38& 39.521.67& & 0.10(n=4)& 2.240.93& 2.481.03& & 0.50(n=3)& 7.170.35& 9.090.45&
0.74(n=3)& 2.800.18& 33.272.14*&& 0.99(n=3)& 11.381.93& 43.327.38& & 0.15(n=4)& 3.323.14& 4.404.15& & 0.98(n=3)& 0.870.04& 13.220.64&
0.99(n=4)& 1.950.24*& 68.208.58*&& 1.50(n=4)& 31.416.98& 55.5412.34& & 0.20(n=3)& 1.060.92& 1.351.17& & 1.50(n=4)& 9.891.18& 21.732.60&
& & & & 2.00(n=5)& 26.953.67& 77.2010.51*& & & & & & 1.98(n=4)& 4.320.49*& 28.383.21*&
& & & & 4.84(n=3)& 15.277.77& 128.5965.46*& & & & & & 2.50(n=3)& 0.380.37*& 11.5411.11&
&
Poloxamer&P407&
Concentration&
(%&w/v)&
Ibuprofen& & Gliclazide& & Atenolol& & Propranolol&
&
Solution&
intrinsic&
Aqueous&
intrinsic&
& Solution&
intrinsic&
Aqueous&
intrinsic&
& Solution&
intrinsic&
Aqueous&
intrinsic&
& Solution&
intrinsic&
Aqueous&
intrinsic&
0&
3.980.50&
(n=4)&
3.980.50& & 27.505.78&
(n=3)&
27.505.78& & 2.632.19&
(n=5)&
2.632.19& & 4.470.05&
(n=3)&
4.470.05&
0.5&
4.331.08&
(n=3)&
97.8924.46& & 14.874.2&
(n=3)&
18.835.32& & 2.120.35&
(n=3)&
2.650.44& & 3.081.00&
(n=3)&
7.492.43&
1&
3.952.69&
(n=3)&
130.3688.59& & 19.6410.49&
(n=3)&
29.4815.74& & 2.260.41&
(n=3)&
2.950.53& & 4.110.27&
(n=3)&
14.480.95&
2&
2.402.12&
(n=3)&
155.47136.8& & 20.582.13&
(n=3)&
32.623.38& & 2.620.14&
(n=3)&
3.260.17& & 4.010.51& 19.972.55&
5&
12.2416.24&
(n=3)&
1705.732263*& & 13.901.88&
(n=3)&
49.516.71& & 2.710.73&
(n=3)&
3.881.04& & & &
10&
& & & & & & & & & 3.201.14&
(n=3)&
75.2926.87*&
&
&
&
&
 
